These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15749695)

  • 1. Mutation of active site residues of insulin-degrading enzyme alters allosteric interactions.
    Song ES; Daily A; Fried MG; Juliano MA; Juliano L; Hersh LB
    J Biol Chem; 2005 May; 280(18):17701-6. PubMed ID: 15749695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A monomeric variant of insulin degrading enzyme (IDE) loses its regulatory properties.
    Song ES; Rodgers DW; Hersh LB
    PLoS One; 2010 Mar; 5(3):e9719. PubMed ID: 20300529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of conserved residues in the active site of insulin-degrading enzyme.
    Perlman RK; Gehm BD; Kuo WL; Rosner MR
    J Biol Chem; 1993 Oct; 268(29):21538-44. PubMed ID: 8104941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolytic fragments of insulysin (IDE) retain substrate binding but lose allosteric regulation.
    Song ES; Cady C; Fried MG; Hersh LB
    Biochemistry; 2006 Dec; 45(50):15085-91. PubMed ID: 17154546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development.
    Song ES; Juliano MA; Juliano L; Hersh LB
    J Biol Chem; 2003 Dec; 278(50):49789-94. PubMed ID: 14527953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anion activation site of insulin-degrading enzyme.
    Noinaj N; Song ES; Bhasin S; Alper BJ; Schmidt WK; Hersh LB; Rodgers DW
    J Biol Chem; 2012 Jan; 287(1):48-57. PubMed ID: 22049080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the allosteric regulatory site of insulysin.
    Noinaj N; Bhasin SK; Song ES; Scoggin KE; Juliano MA; Juliano L; Hersh LB; Rodgers DW
    PLoS One; 2011; 6(6):e20864. PubMed ID: 21731629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of residues in the insulin molecule important for binding to insulin-degrading enzyme.
    Affholter JA; Cascieri MA; Bayne ML; Brange J; Casaretto M; Roth RA
    Biochemistry; 1990 Aug; 29(33):7727-33. PubMed ID: 2271531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Determinants of Substrate Specificity in Human Insulin-Degrading Enzyme.
    Stefanidis L; Fusco ND; Cooper SE; Smith-Carpenter JE; Alper BJ
    Biochemistry; 2018 Aug; 57(32):4903-4914. PubMed ID: 30004674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward Allosterically Increased Catalytic Activity of Insulin-Degrading Enzyme against Amyloid Peptides.
    Kurochkin IV; Guarnera E; Wong JH; Eisenhaber F; Berezovsky IN
    Biochemistry; 2017 Jan; 56(1):228-239. PubMed ID: 27982586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitin is a novel substrate for human insulin-degrading enzyme.
    Ralat LA; Kalas V; Zheng Z; Goldman RD; Sosnick TR; Tang WJ
    J Mol Biol; 2011 Feb; 406(3):454-66. PubMed ID: 21185309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP effects on insulin-degrading enzyme are mediated primarily through its triphosphate moiety.
    Song ES; Juliano MA; Juliano L; Fried MG; Wagner SL; Hersh LB
    J Biol Chem; 2004 Dec; 279(52):54216-20. PubMed ID: 15494400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme.
    Malito E; Ralat LA; Manolopoulou M; Tsay JL; Wadlington NL; Tang WJ
    Biochemistry; 2008 Dec; 47(48):12822-34. PubMed ID: 18986166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE.
    Im H; Manolopoulou M; Malito E; Shen Y; Zhao J; Neant-Fery M; Sun CY; Meredith SC; Sisodia SS; Leissring MA; Tang WJ
    J Biol Chem; 2007 Aug; 282(35):25453-63. PubMed ID: 17613531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the binding of the fluorescent ATP analog TNP-ATP to insulysin.
    Yao H; Hersh LB
    Arch Biochem Biophys; 2006 Jul; 451(2):175-81. PubMed ID: 16723115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of zinc ligands of the insulin-degrading enzyme.
    Perlman RK; Rosner MR
    J Biol Chem; 1994 Dec; 269(52):33140-5. PubMed ID: 7806544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational, kinetic, and NMR studies of the roles of conserved glutamate residues and of lysine-39 in the mechanism of the MutT pyrophosphohydrolase.
    Harris TK; Wu G; Massiah MA; Mildvan AS
    Biochemistry; 2000 Feb; 39(7):1655-74. PubMed ID: 10677214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple allosteric sites are involved in the modulation of insulin-degrading-enzyme activity by somatostatin.
    Tundo GR; Di Muzio E; Ciaccio C; Sbardella D; Di Pierro D; Polticelli F; Coletta M; Marini S
    FEBS J; 2016 Oct; 283(20):3755-3770. PubMed ID: 27579517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulysin: an allosteric enzyme as a target for Alzheimer's disease.
    Song ES; Hersh LB
    J Mol Neurosci; 2005; 25(3):201-6. PubMed ID: 15800373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity.
    Ciaccio C; Tundo GR; Grasso G; Spoto G; Marasco D; Ruvo M; Gioia M; Rizzarelli E; Coletta M
    J Mol Biol; 2009 Feb; 385(5):1556-67. PubMed ID: 19073193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.